Allay Therapeutics key facts
as of Oct 2026- Developer of sustained analgesic products designed to provide post-surgical pain management and recuperation for patients and physicians.
- Allay Therapeutics is valued at approximately $126.0M as of Oct 2026, set at its later-stage round, Jun 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $174.8M across 3 recorded rounds; the latest was Early Stage VC ($45.0M) in Jan 2025.
- Notable investors include New Enterprise Associates, Temasek Holdings, EDBI, SGInnovate, Vertex Growth — 19 tracked in total.
- Allay Therapeutics has filed 4 Form Ds with the SEC since 2021, most recently Feb 2025 ($45.0M sold to 18 investors).
- Status: Privately Held (backing).
Valued at $126.0M at its later-stage round, Jun 2025. Nothing has traded since.
- ·The complete investor list: 19 names
- ·Watch Allay Therapeutics: the Monday email on marks, rounds and moves
Allay Therapeutics funding rounds
3 roundsWho backs Allay Therapeutics
19+Allay Therapeutics valuation
Allay Therapeutics was valued at $126 million at its later-stage round in Jun 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Allay Therapeutics raised?
Allay Therapeutics has raised $175 million across 3 recorded rounds since 2020. The largest was an $86.9 million later-stage round in Sep 2021; the most recent was a $45 million early-stage round in Jan 2025.
Allay Therapeutics has filed 4 Form Ds with the SEC since 2021, most recently in Feb 2025 ($45 million sold to 18 investors).
Allay Therapeutics investors
19 investors are on record for Allay Therapeutics, including New Enterprise Associates, Temasek Holdings, EDBI and SGInnovate. By type, the record holds 6 venture capital firms and 1 family office. The early-stage round in Jan 2025 drew 18 investors.
About Allay Therapeutics
Developer of sustained analgesic products designed to provide post-surgical pain management and recuperation for patients and physicians. The company's platform combines validated local analgesics and biopolymers in dissolvable candidates designed to deliver pain relief and address the drawbacks of opioids, enabling patients to get through the phase of recuperation in a simplified way.
- Sector
- Healthcare
- HQ
- San Jose, CA, United States
- Founded
- 2016
- Employees
- 50
- Website
- allaytx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.